Ngokocwaningo lwezokwelapha oluhlanganisa izikhungo eziningi oluholwa abacwaningi e-Stanford University School of Medicine, uhlobo olusha lwe-immunotherapy lubonakala luphephile ezigulini ezinomdlavuza wegazi olubizwa ngokuthi i-non-Hodgkin's lymphoma.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of I-non-Hodgkin's lymphoma: diffuse large B- cell lymphoma and follicular lymphoma.
Ngo-2010, abacwaningi abaholwa ngu-Irving Weissman, MD, umqondisi weStanford Stem Cell Biology and Regenerative Medicine Institute, bakhombisa ukuthi cishe wonke amangqamuzana omdlavuza ambozwe ngeprotheyini ebizwa nge-CD47, engadlala i- "do not eat me" Signal kuma-macrophage.
U-Weissman nozakwabo ngokuhamba kwesikhathi benza i-antibody ebizwa ngokuthi i-Hu5F9-G4 evimba amaprotheni e-CD47 futhi ikhuthaze ama-macrophages ukuthi agwinye amangqamuzana omdlavuza. I-Rituximab iyi-antibody ekhonjiswe ukuthi ikhulise isignali ethi "ngidle". Inhlanganisela ye-rituximab ne-Hu5F-G4 ngaphambilini iboniswe ukuthi iyasebenza ngokumelene nomdlavuza womuntu kumamodeli ezilwane, kodwa lona umphumela wokuqala oshicilelwe wezivivinyo zokwelashwa zokwelashwa kwabantu.
Ezigulini ezingama-22 ezazibambe iqhaza kulolu cwaningo, iziguli eziyi-11 zazinciphise kakhulu umdlavuza wasemtholampilo, kanti iziguli eziyi-8 zazisuse zonke izimpawu zomdlavuza. Ezinye iziguli ezintathu esekulingweni azange zisabele ekwelashweni futhi zafa ngenxa yokuqhubeka kwezifo. Abaphenyi babone ukuthi ababambiqhaza babenemiphumela emibi emincane kuphela.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new immunotherapy is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
